Adverse Effect after Radiation Therapy
Abstract
Introduction: The objective of the study is to evaluate and analyze acute and late toxicity of GU genito-urinary tract, estimating GFR as a marker of kidney function, and investigate adverse effect of treatment accordingRTOG scoring system at the at 3-rd and 6-th month of treatment. Material and methods: This study is done at Clinical Center of Kosovo, Oncology Department. 75 patients are evaluated where several variables have been investigated: sex, age, type of primary malignancy, Median TD (tumor dose) evidence over 50 and above 50 Gy. At the beginning, at 3rd and 6th of the treatment patient have been followed by fulfilling in the questioner according RTOG scoring system. Chemotherapy have been employed based on primary tumor site concurrently with radiotherapi Median follow up (FU) have take 6 months. Excluding criteria: Patients with PGUM (Pre Treatment GenitoUrinary Morbidity). G0 of RTOG score at the beginning of treatment to all patients. Results: Our cohort consist of 75 patients with pelvic tumors of which 53 or 70.7% were female and 22 or 29.3% of male. The average age of the patients involved in the research was 57.5 years (SD ± 11.2 years) range 33-77 years. The average age of the female patients involved in the research was 56.1 years (DS ±11.1 years), range 33 – 77 years. The average age of the male patients involved in the research was 60.8 years (SD ±11.1years), range 37 – 74 years. Females are with 3 various types of carcinomas (cervical and endometrial) and males with only 1 (rectal). The 75 patients involved in the research 30 or 40.0% were rectal carcinomas, 28 or 37.3% were cervical carcinomas and 17 or 22.7% were endometrial carcinomas. Conclusions: No significant differences in treatment related site effects between radiotherapy and hemoradiation groups were found. In the follow up after 3 months from 75 patients involved in the research, 11 patients (14.7 %) had G1 GU toxicity that did not need any kind of treatment. 5 patients (6.7%) had G2 GU toxicity. Whereas in the follow up after 6 months 15 patients (20%) had G1 GU toxicity, 7 patients (9.3%) G2 GU toxicity and 4 patients (5.3%) had G3 GU toxicity. Compering grade of toxicity between follow up 3 and 6 months no significant differences have been appeared according RT treatment.
Keywords: Urinary toxicity, adverse effects RTOG, pelvic radiotherapy.
Downloads
Published
How to Cite
Issue
Section
License
Declaration/Copyright transfer:
1. In consideration of the undertaking set out in paragraph 2, and upon acceptance by ANGLISTICUM for publication of the manuscript in the Journal, I/We hereby assign and transfer publication rights to ANGLISTICUM, whereas I/We retain the copyright for the manuscript. This assignment provides ANGLISTICUM the sole right and responsibility to publish the manuscript in its printed and online version, and/or in other media formats.
2. In consideration of this assignment, ANGLISTICUM hereby undertakes to prepare and publish the manuscript in the Journal, subject only to its right to refuse publication if there is a breach of the Author’s warranty in paragraph 4 or if there are other reasonable grounds.
3. Editors and the editorial board of ANGLISTICUM are empowered to make such editorial changes as may be necessary to make the Manuscript suitable for publication.
4. I/We hereby acknowledge that: (a) The manuscript submitted is an original work and that I/We participated in the work substantively and thus I/We hereby are prepared to take public responsibility for the work; (b) I/We hereby have seen and approved the manuscript as submitted and that the manuscript has not either been published, submitted or considered for publication elsewhere; (c) The text, illustration, and any other materials included in the manuscript do not infringe upon any existing copyright or other rights of anyone.
5. I/We hereby indemnify ANGLISTICUM and the respective Editors of the Journal as mentioned in paragraph 3, and hold them harmless from any loss, expense or damage occasioned by a claim or suit by a third party for copyright infringement, or any suit arising out of any breach of the foregoing warranties as a result of publication of the manuscript.
